Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Study of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy (MOSAIC-TTR)

14 september 2026 uppdaterad av: Bayer

A Prospective, Longitudinal, Multi-center, Observational Study of Acoramidis In Patients With Wild-type or Variant Transthyretin Amyloid Cardiomyopathy (ATTR-CM): MOSAIC-TTR Study

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive heart disease caused by the buildup of an abnormal protein, called transthyretin (TTR), in the heart. This buildup can make it harder for the heart to pump blood and may lead to worsening symptoms over time. Acoramidis is a medicine approved for the treatment of adults with wild-type or hereditary (variant) ATTR-CM. While its benefits have been demonstrated in clinical trials, more information is needed about how it is used and how patients do in everyday medical practice.

The MOSAIC-TTR study is an observational study in France. Participants will receive acoramidis as part of their usual medical care. No experimental treatments or additional medical procedures will be required. The study will collect information directly from participating hospitals and from the Healthcare European Amyloidosis Registry (HEAR; NCT05101304). The main goal of the study is to understand how patients' quality of life, daily functioning, and overall well-being change during the first 12 months of treatment with acoramidis, using questionnaires completed by the patients themselves. The study will also collect information about the characteristics of patients receiving acoramidis, how the medicine is used in routine clinical practice, and its safety and tolerability. The information collected will help improve the understanding of ATTR-CM and may help improve the care of people living with this condition.

Studieöversikt

Status

Rekrytering

Intervention / Behandling

Studietyp

Observationell

Inskrivning (Beräknad)

500

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

      • Many Locations, Frankrike
        • Rekrytering
        • Many locations

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Participants will be recruited from centers that are part of the French Amyloidosis Network or centers that are knowledgeable in the diagnosis and management of transthyretin amyloid cardiomyopathy (ATTR-CM). There are two complementary enrollment pathways: (i) direct recruitment within this study, and (ii) integration of data from the Healthcare Amyloidosis European Registry (HEAR), a multicenter registry maintained by reference centers (see NCT05101304), to enrich the study database.

Beskrivning

Inclusion Criteria:

  • Greater than or equal to 18 years of age
  • Established diagnosis of ATTR-CM with either wild-type TTR or a variant TTR genotype
  • Initiating treatment with acoramidis with the decision to treat having been made by the treating physician prior to study enrolment in accordance with the current French Summary of Product Characteristics (SmPC)

Exclusion Criteria:

  • Any contraindications as listed in the local approved product information
  • Prior treatment with disease-modifying treatment (e.g., tafamidis, TTR silencers and/or depleters)
  • Participation in an investigational trial evaluating new Investigational Medicinal Products or new Investigational Medical Device outside of routine clinical practice
  • Under legal protection (guardianship, curatorship, or other legal protection measures) or deprived of liberty by administrative or judicial decision at the time of inclusion.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Single Arm
Patients will receive acoramidis 712 mg orally BID (twice daily)
356 mg film-coated tablets. The recommended dose is 712 mg (two tables, 356 mg) orally twice daily, corresponding to a total daily dose of 1424 mg.
Andra namn:
  • BEYONTTRA
  • BAY3684938

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Patient Reported Outcome Measure: Amylo-AFFECT-QOL score
Tidsram: At 3, 6, 9, and 12 months after initiation of acoramidis
Change from baseline in Amylo-AFFECT-QOL total score
At 3, 6, 9, and 12 months after initiation of acoramidis
Patient Reported Outcome Measure: KCCQ-23 score
Tidsram: At 3, 6, 9, and 12 months after initiation of acoramidis
Change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ-23) total score
At 3, 6, 9, and 12 months after initiation of acoramidis
Patient Reported Outcome Measure: EQ-5D-3L index score
Tidsram: At 3, 6, 9, and 12 months after initiation of acoramidis
3L index score of EQ-5D Health-Related Quality of Life Questionnaire
At 3, 6, 9, and 12 months after initiation of acoramidis
Patient Reported Outcome Measure: EQ VAS score
Tidsram: At 3, 6, 9, and 12 months after initiation of acoramidis
Visual Analog scale score of EQ-5D Health-Related Quality of Life Questionnaire
At 3, 6, 9, and 12 months after initiation of acoramidis

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Demographic characteristics: Age
Tidsram: Before treatment with acoramidis
Age of patients initiating treatment with acoramidis
Before treatment with acoramidis
Demographic characteristics: Sex
Tidsram: Before treatment with acoramidis
Sex of patients initiating treatment with acoramidis
Before treatment with acoramidis
Demographic characteristics: Body Mass Index
Tidsram: Before treatment with acoramidis
Body Mass Index of patients initiating treatment with acoramidis
Before treatment with acoramidis
Clinical characteristics: Time between diagnosis and treatment initiation
Tidsram: Before treatment with acoramidis
Time between ATTR-CM diagnosis and treatment initiation
Before treatment with acoramidis
Clinical characteristics: ATTR-CM diagnosis
Tidsram: Before treatment with acoramidis
ATTR-CM diagnosis (genetic status including mutation type [if applicable], phenotype)
Before treatment with acoramidis
Clinical characteristics: ATTR-CM manifestations
Tidsram: Before treatment with acoramidis
ATTR-CM manifestations prior to treatment initiation
Before treatment with acoramidis
Clinical characteristics: Comorbidities
Tidsram: Up to 12 months before initiation of acoramidis, and during treatment with acoramidis
ATTR-CM-relevant comorbidities that were either ongoing at treatment initiation, or were previously managed or resolved in the 12 months prior to initiating acoramidis, as well as those that began after initiating acoramidis
Up to 12 months before initiation of acoramidis, and during treatment with acoramidis
Clinical characteristics: Prior medication and procedures
Tidsram: Up to 12 months before initiation of acoramidis
Prior medication taken and procedures performed up to 12 months before initiation of acoramidis
Up to 12 months before initiation of acoramidis
Treatment patterns: Treatment duration
Tidsram: During treatment with acoramidis
Duration of treatment with acoramidis
During treatment with acoramidis
Treatment patterns: Treatment interruptions
Tidsram: During treatment with acoramidis
Proportion of patients with temporary treatment interruptions and reason for interruption
During treatment with acoramidis
Treatment patterns: Treatment discontinuation
Tidsram: During treatment with acoramidis
Proportion of patients with permanent treatment discontinuation and reason for discontinuation
During treatment with acoramidis
Treatment patterns: Time to treatment discontinuation
Tidsram: During treatment with acoramidis
Time to acoramidis treatment discontinuation
During treatment with acoramidis
Treatment patterns: Concomitant medications and procedures
Tidsram: During treatment with acoramidis
Concomitant medications taken and procedures performed during treatment with acoramidis
During treatment with acoramidis
Safety and tolerability: Adverse events
Tidsram: During treatment with acoramidis and up to 6 days after the last intake of acoramidis in case of premature permanent treatment discontinuation
Adverse events (AEs) occurring during treatment with acoramidis and AEs occurring up to 6 days after the last intake of acoramidis if premature permanent treatment discontinuation
During treatment with acoramidis and up to 6 days after the last intake of acoramidis in case of premature permanent treatment discontinuation

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

7 september 2026

Primärt slutförande (Beräknad)

31 december 2028

Avslutad studie (Beräknad)

31 december 2028

Studieregistreringsdatum

Först inskickad

25 augusti 2026

Först inskickad som uppfyllde QC-kriterierna

25 augusti 2026

Första postat (Faktisk)

27 augusti 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

15 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

14 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • 23181

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access.

As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera